Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

Thierry Lacaze-Masmonteil, Juergen Seidenberg, Ian Mitchell, Veerle Cossey, Martin Cihar, Michal Csader, Rienk Baarsma, Marques Valido, Paul F. Pollack, Jessie R. Groothuis, Karel Allegaert, Jacques Lombet, Dominique Haumont, Katleen Plaskie, H. Dele Davies, Reginald S. Sauve, Joanne M. Langley, Karel Liska, Patrick Andre, Pierre LequienNadine Kacet, Fabrice Lapeyre, Barbara Wickenburg-Ennen, Helga Nolte, Peter Andreas Harding, Sandra Ramos, Margarida Carolino, Antónia Marques

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds